All In Biotech

Drug Trial Radar · NCT02964013

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

474

Actual

Start

Dec 13, 2016

Primary completion

Jul 24, 2024

Study completion Jul 24, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation and confirmation phase to estimate the recommended Phase 2 dose (RPTD) for vibostolimab monotherapy or in combination with pembrolizumab, pemetrexed, and carboplatin. Part A will also evaluate the anti-tumor activity of vibostolimab in combination with pembrolizumab plus pemetrexed and carboplatin in participants with non-small cell lung cancer (NSCLC) and vibostolimab (at two dose levels) in combination with pembrolizumab in Japanese participants with gastric cancer. Part B will evaluate the anti-tumor activity of vibostolimab at the RPTD when used as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors in a non-randomized study design. Part B will also evaluate 2 doses of vibostolimab in combination with pembrolizumab in participants with programmed death 1 (PD-1) treatment naïve cancer using a 1:1 randomized study design. Part B is expanded with Amendment 11 to include an additional arm that will compare the safety and PK of a fixed dose of pembrolizumab/vibostolimab coformulation (MK-7684A) to vibostolimab in combination with pembrolizumab administered as separate intravenous infusions. Part A is expanded with Amendment 12 to include an additional arm that will compare the safety and PK of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide. Part B is expanded with Amendment 12 to include evaluation of efficacy of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide and efficacy of pembrolizumab/vibostolimab coformulation in participants from mainland China. The primary hypotheses are that vibostolimab administered as monotherapy or in combination with pembrolizumab is safe and tolerable when administered at the RPTD and that pembrolizumab/vibostolimab coformulation is safe and tolerable when administered as a fixed dose.

Conditions

  • Neoplasms

Interventions

  • vibostolimabBiological

    Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

  • pembrolizumabBiological

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • pemetrexedDrug

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • carboplatinDrug

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

  • pembrolizumab/vibostolimab coformulationBiological

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • cisplatinDrug

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

  • etoposideDrug

    Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 MonthsTime frame: Up to 24 Months
  2. Number of Participants Who Experienced At Least One Adverse Event (AE)Time frame: Up to 28 Months
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 24 Months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.